GlassScriptPhysician profile
Atif Qadeer
NPI 1730160201
$2,021.46
in general payments reported to CMS, 2019-2025
12 companies · $321 in 2025
The $321 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13.61 · 2020: $113 · 2021: $12.69 · 2022: $411 · 2023: $560 · 2024: $591 · 2025: $321.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,472.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,471.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,338.01 | 2022-2025 | Trelegy Ellipta, Nucala, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $262.67 | 2020-2024 | |
| Genzyme Corporation | $143.89 | 2023-2025 | |
| Pfizer INC. | $50.31 | 2022 | |
| Novartis Pharmaceuticals Corporation | $49.64 | 2021-2024 | |
| Grifols USA, LLC | $42.55 | 2023-2024 | Prolastin-C Liquid |
| Ani Pharmaceuticals, INC. | $34.48 | 2025 | Purified Cortrophin Gel |
| Biohaven Pharmaceutical Holding Company LTD. | $26.81 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.78 | 2025 | Ofev |
| Xeris Pharmaceuticals, INC. | $23.67 | 2022 | |
| Janssen Pharmaceuticals, INC | $13.61 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $12.04 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Atif Qadeer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.